Researchers Testing Intense Pulsed Light As An Alternative Treatment for Telangiectatases PDF Print E-mail
Monday, 23 December 2013 11:00
Telangiectatases are knot-like clusters of blood vessels on the skin which can occur in 30 to 50 per cent of patients with Systemic Sclerosis, also known as Scleroderma. Telangiectases tend to occur on the face, neck, and upper limbs and can cause psychological issues for patients.

Currently, doctors use laser treatment to blast the telangiectases and destroy them but this treatment can be painful at the time and result in bruising afterwards , so researchers at the Salford Royal and University of Manchester’s Institute for Inflammation and Repair have been looking for an alternative.

The researchers tested using intense pulsed light (IPL) instead of laser treatment. IPL is often used cosmetically for treating birthmarks and for hair removal. A pilot study treated 19 patients with telangiectases, using IPL on one side of the face and laser treatment on the other. They had three treatments over the course of eight weeks before the results were analysed using close-up photographs and specialist imaging.

The research showed that the effects were roughly comparable but IPL had fewer side effects.

Salford Royal Rheumatology researcher Dr Graham Dinsdale, who is also a Research Associate at the University’s Institute of Inflammation and Repair, said: “While this was only a small-scale pilot study, it does suggest the potential for an alternative, less painful, treatment for telangiectases. We will continue to do all we can to find new and better treatments for patients with Systemic Sclerosis, which is a very serious and debilitating condition.”

Source: The University of Manchester
 
More articles :

» New Formulation of PAH Medication Is Now Available

Epoprostenol for Injection, an improved formulation of epoprostenol that is stable at room temperature, is now commercially available, according to the drug's maker, Actelion Pharmaceuticals US, Inc., of South San Francisco, Calif.The product is...

» Survival In Systemic Sclerosis-Associated Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is a severe complication of systemic sclerosis (SSc) and one of the leading causes of morbidity and mortality in this disease. Although several recent studies have suggested an improvement in the prognosis of...

» Juvenile Localized Scleroderma: Fewer Flares With Methotrexate

was an effective and well-tolerated treatment for in a randomized, double-blind, placebo-controlled trial involving 70 patients with active disease. At the end of the 12-month study, 31 of 46 patients randomized to receive methotrexate had...

» A New Marker of Silent Cardiovascular Disease in Diffuse Scleroderma

Patients with diffuse systemic sclerosis (SSc) and no clinical evidence of (CVD) may, in fact, have subclinical CVD and , and it is detectable. This is the conclusion of a small pilot study from Italy, which showed that elevated plasma levels of ...

» Predictors Of Interstitial Lung Disease In Early Systemic Sclerosis

Introduction: The objective of the present study was to examine the association of baseline demographic andclinical characteristics with sequentially obtained measurements of forced vital capacity (FVC), expressed as apercentage of the predicted...

» Scientists and Clinicians Address Diagnosis and Treatment for Autoimmune and Autoinflammatory Diseases

Autoimmune and autoinflammatory diseases are a major health issue. The National Institutes of Health reports that up to 23.5 million Americans are afflicted. The American Autoimmune Related Diseases Association reports the number is closer to 50...